IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain
出版年份 2021 全文链接
标题
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain
作者
关键词
Nonsquamous NSCLC, Atezolizumab, Bevacizumab, IMpower150, EGFR, mutation
出版物
Journal of Thoracic Oncology
Volume 17, Issue 2, Pages 309-323
出版商
Elsevier BV
发表日期
2021-10-08
DOI
10.1016/j.jtho.2021.09.014
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma
- (2020) Masatoshi Kudo Cancers
- The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes
- (2020) Floris Dammeijer et al. CANCER CELL
- Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
- (2020) Roy S. Herbst et al. NEW ENGLAND JOURNAL OF MEDICINE
- First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?
- (2019) Masayuki Takeda et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
- (2019) Martin Reck et al. Lancet Respiratory Medicine
- Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
- (2019) Howard West et al. LANCET ONCOLOGY
- Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib
- (2019) Yuxin Mu et al. Targeted Oncology
- Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR , ALK , ROS1 , KRAS or BRAF
- (2019) Xibin Zhuang et al. Cancer Medicine
- Immune Checkpoint Blockade – How Does It Work in Brain Metastases?
- (2019) Mihaela Lorger et al. Frontiers in Molecular Neuroscience
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tissue-Specific Immunoregulation: A Call for Better Understanding of the “Immunostat” in the Context of Cancer
- (2018) William Pao et al. Cancer Discovery
- Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab
- (2018) Bharathi Vennapusa et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study
- (2018) Leora Horn et al. EUROPEAN JOURNAL OF CANCER
- Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis
- (2017) Chee Khoon Lee et al. Journal of Thoracic Oncology
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
- (2017) Priti S. Hegde et al. SEMINARS IN CANCER BIOLOGY
- Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
- (2017) Paul C. Tumeh et al. Cancer Immunology Research
- Estimating Survival in Patients With Lung Cancer and Brain Metastases
- (2017) Paul W. Sperduto et al. JAMA Oncology
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma
- (2016) A. Ilhan-Mutlu et al. MOLECULAR CANCER THERAPEUTICS
- Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer
- (2016) Ming-Szu Hung et al. Oncology Letters
- Prognostic effect of liver metastasis in lung cancer patients with distant metastasis
- (2016) Yijiu Ren et al. Oncotarget
- Metastatic sites and survival in lung cancer
- (2014) M. Riihimäki et al. LUNG CANCER
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Incidence of brain metastasis at initial presentation of lung cancer
- (2014) J. Lee Villano et al. NEURO-ONCOLOGY
- Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
- (2013) Laurence Zitvogel et al. IMMUNITY
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo
- (2011) A. M. Paterson et al. JOURNAL OF IMMUNOLOGY
- The Novel Costimulatory Programmed Death Ligand 1/B7.1 Pathway Is Functional in Inhibiting Alloimmune Responses In Vivo
- (2011) J. Yang et al. JOURNAL OF IMMUNOLOGY
- B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance
- (2010) J.-J. Park et al. BLOOD
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started